Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF

Heart

Volumn 101, Issue 1, 2015, Pages 50-57

  Van Boven, Nick ^a,b   Windecker, Stephan ^c   Umans, Victor A ^a   Van Domburg, Ron T ^d   Kardys, Isabella ^d   Akkerhuis, K Martijn ^d   Van Geuns, Robbert Jan ^d   Serruys, Patrick W ^d   Magro, Michael ^d   Räber, Lorenz ^c   Boersma, Eric ^d  

^a Medical Centre Alkmaar   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF BERN   (Switzerland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; STENT THROMBOSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ELUTING STENT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INCIDENCE; KAPLAN MEIER METHOD; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTHESIS; REGISTER; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SWITZERLAND; TIME;

CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STROKE VOLUME; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84919767467     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305743     Document Type: Article

References (27)

1. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
2. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-23.
3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
5. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-9.
6. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-48.
7. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
8. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
9. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-34.
10. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008; 118: 1138-45.
11. Hassan AK, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010; 31: 1172-80.
12. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125: 1110-21.
13. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-9.
14. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-74.
15. Keelan PC, Johnston JM, Koru-Sengul T, et al. Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions or=50% having percutaneous coronary revascularization. Am J Cardiol 2003; 91: 1168-72.
16. Wallace TW, Berger JS, Wang A, et al. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2009; 103: 355-60.
17. Sardi GL, Gaglia MA Jr, Maluenda G, et al. Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction. Am J Cardiol 2012; 109: 344-51.
18. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51: 986-90.
19. Cayla G, Hulot JS, O'Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011; 306: 1765-74.
20. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
21. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399-409.
22. Biondi ZG, Moretti C, Abbate A, et al. Percutaneous coronary stenting in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. EuroIntervention. 2007; 3: 409-15.
23. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-4.
24. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78.
25. Aslam F, Blankenship JC. Coronary artery stenting in patients with severe left ventricular dysfunction. J Invasive Cardiol 2005; 17: 656-8.
26. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51.
27. Nusca A, Lipinski MJ, Varma A, et al. Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention. Am J Cardiol 2008; 102: 679-82.